ImmuPharma targets regulatory approval as follow-up study confirms “outstanding” safety profile of Lupuzor™ – Proactive Investors

12th August 2019

To view commentary click here

 

Share this article

Cookies

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the Cookie Policy